Bevacizumab plus xelox as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer

被引：0
|
作者：
Gruenberger, Thomas
Tamandl, Dietmar
Herbst, Friedrich
Scheithauer, Werner
Zielinski, Christoph
Gruenberger, Birgit
机构：
[1] Med Univ Vienna, Dept Gen Surg, Hepatobiliary Serv, Vienna, Austria
[2] Med Univ Vienna, Dept Oncol, Vienna, Austria
来源：
ANNALS OF ONCOLOGY | 2006年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：128 / 128
页数：1
相关论文
共 50 条
  • [31] Cetuximab plus XELIRI or XELOX for first-line therapy of metastatic colorectal cancer
    Moosmann, Nicolas
    Heinemann, Volker
    CLINICAL COLORECTAL CANCER, 2008, 7 (02) : 110 - 117
  • [32] Observational cohort study focused on treatment continuity of patients administered XELOX plus bevacizumab for previously untreated metastatic colorectal cancer
    Kotaka, Masahito
    Ikeda, Fusao
    Tsujie, Masaki
    Yoshioka, Shinichi
    Nakamoto, Yoshihiko
    Ishii, Takaaki
    Kyogoku, Takahisa
    Kato, Takeshi
    Tsuji, Akihito
    Kobayashi, Michiya
    ONCOTARGETS AND THERAPY, 2016, 9 : 4113 - 4120
  • [33] Retrospective analysis of capecitabine and oxaliplatin (XELOX) plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer
    Uchima, Yasutake
    Nishii, Takafumi
    Iseki, Yasuhito
    Ishii, Mariko
    Hiramatsu, Soichiro
    Iwauchi, Takehiko
    Morimoto, Junya
    Kosaka, Kinshi
    Tei, Seika
    Takeuchi, Kazuhiro
    MOLECULAR AND CLINICAL ONCOLOGY, 2014, 2 (01) : 134 - 138
  • [34] FOLFOXIRI plus Bevacizumab in metastatic colorectal Cancer
    不详
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2020, 58 (07): : 630 - 630
  • [35] Continuing Single-Agent Bevacizumab as Maintenance Therapy After Induction XELOX (or FOLFOX) Plus Bevacizumab in First-Line Treatment of Metastatic Colorectal Cancer
    Diaz-Rubio, Eduardo
    ONCOLOGIST, 2012, 17 (11): : 1426 - 1428
  • [36] Updated efficacy and subgroup analysis of first-line serplulimab plus bevacizumab and XELOX versus placebo plus bevacizumab and XELOX in metastatic colorectal cancer: A phase 2/3 study.
    Xu, Rui-Hua
    Wang, Feng
    Wang, Zi-Xian
    Peng, Junjie
    Liang, Xinjun
    Cheng, Ying
    Deng, Yanhong
    Chen, Kehe
    Zhang, Mingjun
    Zhang, Jingdong
    Wang, Wei
    Cao, Bangwei
    Jin, Yongdong
    Sun, Meili
    Lin, Yuan
    Luo, Suxia
    Li, Zhen
    Yang, Liu
    Wang, Qingyu
    Zhu, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 170 - 170
  • [37] Intensified First Line Therapy of the metastatic colorectal Cancer with FOLFOXIRI plus Bevacizumab
    Ruessel, J.
    ONKOLOGE, 2015, 21 (04): : 334 - 335
  • [38] Xelox (capecitabine plus oxaliplatin) as neoadjuvant chemotherapy of unresectable liver metastases in colorectal cancer patients
    Coskun, U.
    Buyukberber, S.
    Yaman, E.
    Uner, A.
    Er, O.
    Ozkan, M.
    Dikilitas, M.
    Oguz, M.
    Yildiz, R.
    Yamac, D.
    Ozturk, B.
    Kaya, A. O.
    Benekli, M.
    NEOPLASMA, 2008, 55 (01) : 65 - 70
  • [39] A phase II study of dose reductive XELOX plus bevacizumab in elderly or vulnerable patients with metastatic colorectal cancer: MCSGO-1202
    Nakata, K.
    Sakai, D.
    Hasegawa, J.
    Kato, T.
    Murata, K.
    Ikenaga, M.
    Kudo, T.
    Uemura, M.
    Satoh, T.
    Mizushima, T.
    Doki, Y.
    Eguchi, H.
    ANNALS OF ONCOLOGY, 2021, 32 : S168 - S168
  • [40] A Single Arm, Phase II Study of Simvastatin Plus XELOX and Bevacizumab as First-Line Chemotherapy in Metastatic Colorectal Cancer Patients
    Kim, Youjin
    Kim, Tae Won
    Han, Sae Won
    Ahn, Joong Bae
    Kim, Seung Tae
    Lee, Jeeyun
    Park, Joon Oh
    Park, Young Suk
    Lim, Ho Yeong
    Kang, Won Ki
    CANCER RESEARCH AND TREATMENT, 2019, 51 (03): : 1128 - 1134
12345